The authors trace a decisive shift in how the field understands the disorder. Early research attributed dry eye primarily to insufficient tear secretion or excessive tear evaporation, treating the tear film as the sole culprit. Advances in mechanistic research have moved the academic consensus away from that tear film-centric perspective toward an integrated framework of disrupted overall ocular surface homeostasis. In this view, the tear film is just one node in a network, and the chronic, refractory character of the disease emerges from interactions across the whole ocular surface rather than from a single deficit in tear production or stability.

According to the review, the pathological cascade begins with the corneal epithelium. When this thin protective layer is injured, its barrier function breaks down, and cells release damage-associated molecular patterns, molecular alarm signals that alert the innate immune system. Responding immune cells secrete abundant proinflammatory mediators, which in turn further impair epithelial architecture and damage goblet cells, the specialized cells that produce the mucus component of the tear film. The result is a feedback loop in which barrier failure fuels inflammation, and inflammation deepens barrier failure, setting the stage for disease chronicity.

The third player in the circuit, and arguably its central regulator, is the corneal nerve. The review describes how corneal nerves undergo both morphological and functional remodeling under chronic inflammatory and hyperosmotic stimuli. Patients and experimental models show reduced nerve fiber density alongside hyperalgesia, a state in which sensations become amplified and painful. At the same time, stressed nerves continuously secrete neuropeptides, signaling molecules that induce neurogenic inflammation, a form of immune activation driven directly by neural output. Neural dysfunction also suppresses tear secretion and hinders epithelial repair, so the very system meant to sense and protect the ocular surface becomes a persistent amplifier of immune dysregulation and tissue injury.

It is this three-way interdependence that the authors elevate into a formal conceptual model, which they call the epithelial–immune–neural unit. In their framework, a disrupted epithelial barrier releases inflammatory cytokines that trigger excessive immune activation and corneal neural damage. Injured nerves, in turn, secrete neuropeptides that further amplify immune responses. Sustained aberrant immune and neural signaling then jointly inhibit epithelial repair and regeneration. Because each compartment regulates the others bidirectionally, the system settles into a vicious cycle in which every round of injury primes the next. Analyses confined to any single compartment, the authors contend, cannot fully explain the diverse symptoms and chronic progression that define dry eye disease in the clinic.

The model has immediate explanatory power for a puzzle that has long frustrated clinicians: why symptoms so often persist even when tear quantity or quality appears to improve. If chronic pain and fluctuating vision are driven by neural remodeling and neurogenic inflammation rather than by the tear film alone, then therapies aimed solely at wetting the surface or broadly suppressing inflammation will leave key arms of the circuit untouched. The review systematically collates these interconnected mechanisms precisely because, in the authors’ assessment, no prior review had done so, leaving the field without a unified account of why the disease becomes refractory.

On the therapeutic side, the authors take a candid look at existing anti-inflammatory strategies and their inherent limitations. Their analysis clarifies the fundamental reason why single symptomatic interventions fail to block the vicious cycle of the tripartite system: a drug that targets only one arm of the network leaves the other two arms free to regenerate the pathology. Broad-spectrum anti-inflammatory approaches, while valuable, do not address the specific molecular conversations occurring between epithelium, immune cells, and nerves, and therefore cannot dismantle the circuit as a whole.

The prescription that follows is a change of paradigm. Yu, Wang, and Li propose that future clinical diagnosis and treatment should shift from the conventional broad-spectrum anti-inflammatory approach to precise regulation targeting the multidimensional pathological interactive network. In practice, that means diagnosing which components of the epithelial–immune–neural unit are driving disease in a given patient and intervening at the specific molecular nodes—cytokine signaling, innate immune activation, neuropeptide release, or neural repair pathways—that sustain the loop. Such targeted intervention strategies, the authors argue, are the logical next step for translational research built on the mechanistic system they describe.

The review also carries implications for how dry eye disease should be studied. By constructing an integrated unit model rather than cataloguing mechanisms compartment by compartment, the authors provide a theoretical scaffold for experiments that manipulate one arm of the circuit and measure consequences in the others. The work was supported by the National Natural Science Foundation of China and the Taishan Scholars Program, and it arrives at a moment when dry eye disease affects a large and growing share of the population worldwide, making mechanistically grounded, precision-oriented therapies an increasingly urgent clinical need.

For patients, the message of the review is quietly radical: dry eye disease is not merely dryness, and it should not be managed as such. It is a chronic inflammatory disorder of an integrated neuroimmune-epithelial system, in which damaged barriers, overactive immunity, and remodeling nerves feed one another in a loop that widens with time. Breaking that loop, the authors conclude, will require therapies designed for the network as a whole—precise, multidimensional regulation in place of one-size-fits-all symptom relief. If the field follows the roadmap laid out in this synthesis, the next generation of dry eye treatments may look far less like better eye drops and far more like targeted modulators of the biological circuit that keeps the disease alive.

Subject of Research: Inflammatory mechanisms and epithelial–immune–neural interactions in dry eye disease

Article Title: Inflammation as a central mechanism: interactions among epithelial, immune, and neural units in dry eye disease and their therapeutic implications

Article References: Yu, H., Wang, X., & Li, S. (2026). Inflammation as a central mechanism: interactions among epithelial, immune, and neural units in dry eye disease and their therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08891-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08891-8

Keywords: dry eye disease, inflammation, ocular surface, corneal nerves, epithelial barrier, innate immunity, neuropeptides, neurogenic inflammation, epithelial-immune-neural unit, targeted therapy, tear film, chronic disease

The research focuses on a family of CD4-positive helper T cells known as Th17 cells, which have occupied an ambiguous position in cystic fibrosis immunology for over a decade. Elevated levels of interleukin-17, the signature cytokine of this lineage, were initially interpreted as a hallmark of pathology, since IL-17 drives neutrophil recruitment and tissue-destructive inflammation. Later work complicated that picture by showing that Th17 cells are functionally heterogeneous. Conventional Th17 cells, which co-produce IL-17 alongside the anti-inflammatory cytokine IL-10 and the epithelial-supporting IL-22, actually promote mucosal homeostasis and barrier integrity. By contrast, a distinct pro-inflammatory population, termed Th1/17 for its co-expression of interferon-gamma and IL-17 in the absence of IL-10, has been implicated in chronic inflammatory diseases ranging from multiple sclerosis to Crohn’s disease. Which of these faces Th17 presents in the cystic fibrosis lung remained an open question.

To resolve it, the team analysed T cells isolated from explanted lungs and blood of people with cystic fibrosis, alongside non-CF lung tissue and healthy donor blood. Using high-dimensional flow cytometry and unsupervised clustering based on chemokine receptor expression, they identified two pathogenic subsets, CCR5-positive Th1/17 cells and pro-inflammatory CCR5-positive Th17 cells, that were markedly enriched in cystic fibrosis lungs compared with both patient blood and non-CF lungs. Critically, this enrichment was not a general feature of the disease. The pathogenic subsets expanded selectively in lungs chronically colonized by Pseudomonas aeruginosa, irrespective of whether other pathogens such as Staphylococcus aureus were also present. In Pseudomonas-negative patients, protective conventional Th17 cells predominated instead, pointing to the bacterium itself as the upstream driver of the pathological shift.

The functional consequences of this shift were striking. In an air-liquid interface model of primary human bronchial epithelium, a laboratory system that recapitulates the differentiated, ciliated airway lining, activated Th1/17 and pro-inflammatory Th17 cells caused extensive disruption of epithelial integrity. Immunofluorescence staining for zonula occludens-1, a core component of tight junctions, revealed discontinuous, fragmented junctional patterns in cultures exposed to these subsets, while conventional Th17 cells left the barrier largely intact. Quantitative artificial intelligence-assisted image analysis confirmed the selective loss of junctional continuity. The pathogenic subsets also provoked a significantly stronger inflammatory response from epithelial cells, which released elevated amounts of cytokines and chemokines including IL-8, IL-6, CCL20 and RANTES, molecules that in turn recruit further immune cells to the airway wall.

Transcriptomic profiling by RNA sequencing deepened the picture. Pulmonary Th1/17 and pro-inflammatory Th17 cells from Pseudomonas-infected cystic fibrosis lungs displayed a distinctive signature of 210 upregulated and 40 downregulated genes compared with the same subsets in blood and non-CF lungs. Gene set enrichment analysis showed that lung-resident pathogenic cells upregulated 21 pathways linked to bacterial response, inflammation and tissue remodelling, with high-ranking genes including PPARG, CEBPD and IRAK2, transcriptional regulators known to shape Th17 differentiation and function. Peripheral counterparts of the same subsets showed a largely repressed programme, indicating that the lung environment itself actively reconfigures these cells rather than merely recruiting pre-formed effectors from the circulation.

T cell receptor sequencing added a crucial layer of evidence. The researchers found a significant expansion of private clonotypes, receptor sequences unique to individual patients, within cystic fibrosis lungs, accounting for 45.8 percent of the Th1/17 repertoire compared with roughly 22 percent in non-CF lungs. Among the most expanded clonotypes, some were shared between Th1/17 and pro-inflammatory Th17 cells but minimally represented in Th1 or conventional Th17 populations, suggesting a common antigenic experience driving functional convergence. Partial overlap between the receptor repertoires of pathogenic subsets and conventional Th17 cells, but not Th1 cells, provided a molecular fingerprint of lineage relationships that the team then tested experimentally.

That experimental work centred on dendritic cells, the antigen-presenting sentinels that instruct T cell fate. The team exposed human monocyte-derived dendritic cells to 26 clinical Pseudomonas aeruginosa strains isolated longitudinally from Danish cystic fibrosis patients, spanning early isolates taken at disease onset and late isolates collected after years of chronic colonization. Late strains were internalized more efficiently and persisted longer inside dendritic cells than the reference laboratory strain PAO1. More importantly, clinical isolates skewed the dendritic cell cytokine output toward a polarizing cocktail of IL-1β and IL-23, the two cytokines known to drive interferon-gamma-producing Th17 differentiation, while relatively suppressing IL-12, the canonical Th1-polarizing signal. IL-1β secretion correlated with intracellular bacterial persistence, and clinical strains also triggered strong release of CCL20, the chemokine that recruits CCR6-positive Th17 cells to sites of infection.

In antigen-specific co-culture assays, the researchers then demonstrated that conventional Th17 cells, not Th1 cells, are the precursors of the pathogenic populations. After ten days of co-culture with Pseudomonas-infected dendritic cells, sorted conventional Th17 cells acquired robust interferon-gamma and IL-17 co-expression, whereas Th1 cells never converted. Unexpectedly, early clinical isolates lacking the classic adaptations of chronic infection, such as reduced motility and biofilm formation, were at least as effective as late isolates at inducing this conversion, and some strains exceeded the levels seen with PAO1. The reprogramming extended to transcription factors: converted cells upregulated C/EBPδ and PPARγ, and in some cases BATF3, mirroring the profile of lung-resident pathogenic Th17 cells from patients. This indicates that the immunostimulatory virulence determinants responsible are present from the earliest stages of colonization and retained throughout bacterial adaptation to the cystic fibrosis lung.

The study thereby rewrites a long-standing paradigm. Adaptive immune dysfunction in cystic fibrosis was widely assumed to emerge only in late-stage disease, but the new data show that Pseudomonas aeruginosa can corrupt protective Th17 immunity from the moment it establishes infection, creating a self-sustaining immunopathological loop in which reprogrammed T cells damage the epithelium, epithelial cells release chemokines that recruit more Th17 cells, and the resulting inflammation further impairs bacterial clearance. The findings carry direct therapeutic implications. IL-1 receptor blockade with anakinra has already been shown to mitigate Pseudomonas-driven airway inflammation in cystic fibrosis, and IL-23 inhibitors are clinically established in other chronic inflammatory diseases, although safety concerns about prolonged IL-1β blockade and the need to preserve protective mucosal immunity remain. The authors caution that their lung cohort reflects advanced disease and that the specific bacterial or host antigens driving the T cell skewing are still unknown. Even so, selectively depleting Th1/17 and pro-inflammatory Th17 cells, or blocking their generation from conventional Th17 precursors, now stands as a credible precision immunomodulatory strategy, one that could address the inflammation that persists even in patients receiving CFTR modulator therapy.

Subject of Research: Pseudomonas aeruginosa-driven reprogramming of Th17 cells in cystic fibrosis lung immunopathology

Article Title: Pseudomonas aeruginosa induces the generation of pathogenic IFNγ+Th17 cells that promote lung damage and chronic inflammation in cystic fibrosis

Article References: Dusetti, I., Conte, G., Chiara, M., Puccio, S., Guidone, D., Ricciardelli, E., Cibella, J., Ronzio, M., Dolfini, D., Rossi, E., Landini, P., Ascagni, M., Orlandi, R., Damarco, F., Palleschi, A., Gramegna, A., Blasi, F., Lugli, E., Galietta, L. J., … Paroni, M. (2026). Pseudomonas aeruginosa induces the generation of pathogenic IFNγ+Th17 cells that promote lung damage and chronic inflammation in cystic fibrosis. Nature Microbiology. https://doi.org/10.1038/s41564-026-02469-2

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02469-2

Keywords: cystic fibrosis, Pseudomonas aeruginosa, Th17 cells, interferon-gamma, dendritic cells, IL-23, IL-1β, epithelial barrier, T cell receptor, mucosal immunity, chronic inflammation, immunotherapy

The research team focused on the distal lung because it is both the site of gas exchange and the most vulnerable part of the respiratory system. Working with human lung epithelial and endothelial cells, as well as precision-cut human lung tissue, the investigators exposed these samples to e-cigarette vapor alone and, in separate experiments, exposed them to vapor followed by infection with a respiratory virus. Within just 24 hours of vapor exposure, the researchers observed damage to the protective barrier of the distal lung, the layer of cells that keeps the airspaces sealed and selectively controls what passes between the air and the blood.

The early cellular response was broad. Vapor exposure triggered cellular stress, impaired autophagy, the internal recycling process cells use to clear damaged components, slowed cell growth and repair, and increased cell death. Each of these processes is central to maintaining the integrity of the alveolar-capillary barrier. When barrier function is compromised, fluid and immune cells can leak into the airspaces, and the lung becomes less able to perform its essential task of transferring oxygen while keeping airborne threats out of the circulation.

Perhaps the most striking result was the persistence of injury. Signs of lung stress remained detectable 10 days after a five-day exposure period had ended. The team documented lasting changes in barrier function, tissue remodeling, and Th1 immunity, a branch of the adaptive immune system that is critical for mounting effective responses against viral infections. Tissue remodeling in the distal lung is a particular concern because, if sustained, it can interfere with the fine architecture of the alveoli and contribute to chronic scarring and reduced lung capacity.

The antiviral consequences were equally significant. In the preclinical models, prior vaping exposure increased the viral burden of SARS-CoV-2 following infection and suppressed several antiviral genes. These genes encode proteins that detect viral genetic material, interfere with viral replication, and recruit immune cells to infected tissue. Their suppression means that when a virus arrives, the lung’s early-warning and containment systems are blunted, potentially allowing the pathogen to replicate to higher levels before an effective immune response can be organized.

Senior author Irina Petrache, MD, a pulmonologist and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health, summarized the implications of the work. Our findings suggest that even short-term vaping exposure can initiate injury in the deepest and most delicate regions of the lung, she said. Importantly, some effects persisted after exposure ended and altered the immune response to a subsequent viral infection. That combination, acute injury followed by lingering immune alteration, is what distinguishes the current findings from earlier work that focused mainly on the immediate effects of vapor exposure.

The study helps explain, at a mechanistic level, why epidemiological and clinical observations have repeatedly linked vaping to lung injury and to greater susceptibility to respiratory infections. Rather than a single toxic event, the research points to a sequence: vapor exposure damages the barrier and stresses the cells, the cells’ repair machinery is slowed, and the immune programming of the tissue shifts in ways that reduce antiviral readiness. Repeated cycles of exposure, the researchers noted, could potentially contribute to chronic lung disease by sustaining cellular injury and disrupting normal repair processes over time.

Technically, the use of precision-cut human lung tissue is an important strength of the study. Unlike isolated cell lines, precision-cut slices preserve the three-dimensional structure of the distal lung, including the relationships between epithelial cells, endothelial cells, and the extracellular matrix that supports them. This means the observed barrier disruption and remodeling reflect interactions among multiple cell types rather than the response of a single cell population. The parallel use of epithelial and endothelial cultures allowed the team to separate contributions from the airside and bloodside linings of the barrier, both of which showed evidence of stress and dysfunction after vapor exposure.

The authors emphasize that the findings will need to be confirmed in future studies in people. Preclinical models, even those built from human cells and tissue, cannot fully capture the complexity of vaping in real-world users, who differ in the devices they use, the e-liquids they inhale, the frequency and depth of their puffing, and their baseline health. Human exposure histories are also far more variable than a controlled five-day exposure regimen. Nonetheless, the demonstration that a brief exposure window can produce measurable and persistent changes in human distal lung tissue provides a biological rationale for concern that complements the population-level associations reported in prior research.

For public health, the message is that risk is not confined to long-term, heavy vaping. If days of exposure can alter barrier integrity, autophagy, repair capacity, and Th1 antiviral immunity in human distal lung tissue, then occasional or new users may not be as protected as commonly assumed, particularly during respiratory virus season. The study also offers researchers concrete mechanistic targets, including barrier repair pathways, autophagy regulation, and antiviral gene expression, that could guide future investigations into which components of e-cigarette vapor drive injury and whether the effects are reversible once exposure stops. As e-cigarette use continues to evolve, work of this kind provides the cellular-level evidence needed to assess its consequences for lung health with greater precision.

Subject of Research: Effects of brief e-cigarette vapor exposure on human distal lung tissue and antiviral immune defenses

Article Title: Even brief e-cigarette use can cause lasting lung damage and weaken defenses against respiratory viruses, study finds

Article References: Even brief e-cigarette use can cause lasting lung damage and weaken defenses against respiratory viruses, study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: e-cigarettes, vaping, lung injury, distal lung, epithelial barrier, autophagy, Th1 immunity, SARS-CoV-2, antiviral genes, JCI Insight, National Jewish Health, respiratory infection

The review, authored by Mohammad Ali Mahdiabadi, Asma Moghaddam, and Nafiseh Erfanian, synthesizes evidence that microbiome-derived tryptophan metabolites act as endogenous ligands for the aryl hydrocarbon receptor, or AhR, a transcription factor long studied as a sensor of environmental toxins but now recognized as a central regulator of intestinal homeostasis. In its resting state, AhR sits in the cytoplasm bound to a complex of chaperone proteins. When a ligand binds, the receptor moves into the nucleus, pairs with the AhR nuclear translocator, and switches on genes involved in epithelial maintenance, immune regulation, and detoxification. The gut bacteria supply a steady stream of these ligands: indole-3-aldehyde, indole-3-propionic acid, indole-3-lactic acid, and indole-3-acetic acid, all produced from tryptophan by enzymes such as tryptophanase distributed across Lactobacillus, Clostridium, Bifidobacterium, Bacteroides, and Escherichia coli species.

The foundational observation came from Zelante and colleagues in 2013, who showed that when dietary tryptophan is plentiful, gut lactobacilli shift toward tryptophan catabolism and produce indole-3-aldehyde, which drives AhR-dependent production of interleukin-22. This cytokine, secreted by innate lymphoid cells type 3 and T helper 17 cells, promotes epithelial regeneration, antimicrobial peptide output, and goblet cell function. Later work extended the template to tight junction preservation, mucus maintenance, and intestinal stem cell renewal, establishing the microbiota-tryptophan-AhR axis as a mechanistic linchpin of mucosal health.

Each major metabolite has now been dissected in preclinical colitis models. Indole-3-aldehyde, produced notably by Lactobacillus reuteri, reduces inflammatory cytokines such as interleukin-6, restores the tight junction proteins zonula occludens-1 and occludin, and improves measures of barrier integrity in dextran sulfate sodium colitis. Interestingly, two studies report different degrees of AhR dependence: one found the protection only partially dependent on the receptor, while a more recent analysis documented a strictly AhR- and AMPK-dependent mechanism, with efficacy nearly abolished by receptor inhibition. The discrepancy, the review suggests, likely reflects differences in dosing, treatment duration, and model responsiveness rather than contradictory biology, underscoring that receptor dependence is not an all-or-none property even for a single ligand.

Indole-3-propionic acid, efficiently produced by Clostridium sporogenes, restores tight junction proteins and induces interleukin-22 in ulcerative colitis models, and metabolomic studies consistently find it depleted in IBD patients in correlation with disease severity. Yet its pharmacology is complicated: recent work indicates it can also act directly on heat shock protein 70 to trigger apoptosis of inflammatory Th1 and Th17 cells, independently of AhR or the pregnane X receptor it additionally engages. Indole-3-lactic acid from Lactiplantibacillus plantarum activates both AhR and the antioxidant regulator Nrf2 while suppressing nuclear factor-kappa B, coordinating barrier protection and anti-inflammatory signaling through a single metabolite. Indole-3-acetic acid, by contrast, retains anti-inflammatory activity even when AhR is pharmacologically blocked, showing that at least some protective effects of the indole class operate through receptor-independent routes such as heme oxygenase-1 induction and free radical scavenging.

Downstream of AhR, the review maps an integrated signaling network rather than a simple linear cascade. The AhR-AMPK axis links metabolite sensing to autophagy and mitochondrial resilience in epithelial cells. AhR-Nrf2 crosstalk, though not a strictly hierarchical relationship, induces antioxidant enzymes including superoxide dismutase, catalase, and heme oxygenase-1, blunting the oxidative stress that drives NF-kappa B activation. AhR signaling also directly induces interleukin-22 transcription in immune cells and upregulates the interleukin-10 receptor on epithelia, amplifying anti-inflammatory STAT3 signaling. Finally, AhR-dependent reduction of myosin light chain phosphorylation relaxes the actomyosin cytoskeleton, easing junctional tension and lowering paracellular permeability, the hallmark of the so-called leaky gut.

The review’s most conceptually important contribution may be its insistence that this axis is bidirectional. Active inflammation induces indoleamine 2,3-dioxygenase 1, which diverts tryptophan away from microbial indole synthesis and into the host kynurenine pathway, further depleting protective AhR ligands precisely when the barrier needs them most. Dysbiosis in IBD simultaneously strips away the metabolite-producing taxa themselves, including Lactobacillus, Clostridium clusters, and Allobaculum species. The result is a self-reinforcing loop in which inflammation suppresses the very metabolites that would repair the tissue damage inflammation causes, and CARD9 deficiency, a human genetic risk factor for Crohn’s disease, has been shown to impair this axis by reducing AhR ligand-producing commensals.

Crucially, the authors caution that AhR activation is not uniformly beneficial. Microbial indoles are weak, rapidly metabolized agonists that produce the transient, low-amplitude receptor engagement compatible with tissue repair. Host-derived kynurenine metabolites, or sustained high-affinity activation by compounds such as dioxin, can drive immunosuppressive, barrier-impairing, or even pro-tumorigenic programs. Cell-type-specific transcriptional landscapes add further complexity, and in autoimmune models high-affinity ligands can promote Th17 differentiation, a potentially inflammation-amplifying outcome whose relevance for microbiota-derived indoles remains incompletely characterized. Therapeutic strategies, the review argues, must therefore be ligand-selective, replicating physiological kinetics rather than broadly amplifying AhR signaling.

On the translational front, human evidence remains supportive but limited. Multiple metabolomic cohorts have independently confirmed reduced fecal indole-3-acetate and indole-3-propionate in IBD patients, and direct tissue studies show that AhR expression is reduced in IBD mucosa while remaining functionally responsive to agonist stimulation. A randomized trial of indigo naturalis, an AhR-ligand preparation, achieved significant mucosal healing in ulcerative colitis but was halted early over pulmonary safety concerns, providing proof of concept without an approved therapy. No randomized human trial has yet tested purified indole metabolites, defined probiotic strains, or postbiotic formulations targeting this axis, and most mechanistic data derive from the acute DSS colitis model, which poorly replicates the chronic, immune-mediated pathology of human disease.

The authors propose postbiotics, standardized preparations of purified metabolites such as indole-3-aldehyde, indole-3-propionic acid, and indole-3-lactic acid, as the most practical near-term strategy, offering dose standardization, stability, and direct mechanistic targeting compared with live probiotics. Compounds such as berberine and ganoderic acid A, which enhance endogenous microbial tryptophan metabolism, represent indirect alternatives. But the review closes with measured language: targeting the microbial tryptophan-AhR axis is biologically compelling yet clinically unproven, and its translation will depend on well-designed interventional trials, standardized metabolomic methodology, careful attention to ligand selectivity, and honest reckoning with the feedback loop through which inflammation itself sabotages the repair machinery. Until those data arrive, the trillions of bacteria metabolizing a single dietary amino acid remain both the most promising and the least clinically validated allies in the fight against inflammatory bowel disease.

Subject of Research: Microbiome-derived tryptophan metabolites as ligands of the aryl hydrocarbon receptor that regulate epithelial barrier integrity in inflammatory bowel disease.

Article Title: Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

Article References: Mahdiabadi, M. A., Moghaddam, A., & Erfanian, N. (2026). Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease. MicrobiologyOpen, 15(5), Article e70386. https://doi.org/10.1002/mbo3.70386

Image Credits: AI Generated

DOI: 10.1002/mbo3.70386

Keywords: inflammatory bowel disease, gut microbiome, tryptophan metabolism, aryl hydrocarbon receptor, indole metabolites, epithelial barrier, tight junctions, interleukin-22, postbiotics, dysbiosis, microbiome-targeted therapy, Microbiome